For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and Attruby represents a genuine change. These groundbreaking therapies stabilize the transthyretin protein, slowing its damaging build-up and alleviating the severity of the disease . Patients are now experiencing positive… Read More